Diabetic cardiomyopathy

Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF

This analysis of the Phase 3 ARISE-HF trial explores sex differences in diabetic cardiomyopathy (DbCM) and the efficacy of AT-001. While women presented with worse exercise capacity and health status at baseline, the novel aldose reductase